Imunon (IMNN) Stock Overview
A clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
IMNN Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Imunon, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.31 |
| 52 Week High | US$41.22 |
| 52 Week Low | US$3.14 |
| Beta | 1.93 |
| 1 Month Change | -14.25% |
| 3 Month Change | -36.10% |
| 1 Year Change | -68.00% |
| 3 Year Change | -81.20% |
| 5 Year Change | -97.62% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMNN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.7% | 1.7% | 1.3% |
| 1Y | -68.0% | 27.1% | 15.8% |
Return vs Industry: IMNN underperformed the US Biotechs industry which returned 26.7% over the past year.
Return vs Market: IMNN underperformed the US Market which returned 14.6% over the past year.
Price Volatility
| IMNN volatility | |
|---|---|
| IMNN Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IMNN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IMNN's weekly volatility has decreased from 32% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 25 | Stacy Lindborg | imunon.com |
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
Imunon, Inc. Fundamentals Summary
| IMNN fundamental statistics | |
|---|---|
| Market cap | US$10.16m |
| Earnings (TTM) | -US$14.33m |
| Revenue (TTM) | n/a |
Is IMNN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMNN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$14.33m |
| Earnings | -US$14.33m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.67 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IMNN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 10:12 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Imunon, Inc. is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Kumaraguru Raja | Brookline Capital Markets |